Cipla
Search results
Jun 24, 2024 · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
A global biopharmaceutical company changing patients’ lives by finding new & affordable ways to treat diabetes, cancer & autoimmune diseases.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
Biocon is a unique global biopharmaceutical company changing patients’ lives in over 120 countries. From drug discovery to drug delivery, we make life-saving medicines for the most feared diseases, to extend and significantly improve the quality of life.
It’s a chance to work alongside some of the brightest minds in research, healthcare, pharmaceutical, biotechnology and business sectors. With a talented and diverse team, which works towards the common goal of making healthcare affordable and accessible globally, the possibilities are endless. MORE >>.
We are a global biopharmaceutical company which believes that everyone has a right to affordable quality medicines. Our pioneering spirit paved the way for biotechnology in India, and we continue to apply the same spirit in finding novel approaches to improve patient outcomes today for a better tomorrow.
We are committed to providing everyone, everywhere, affordable access to a speciality portfolio of medicines. We are steadfastly investing in developing novel therapies for diabetes, oncology and immunology. We are strengthening our global reach and economies of scale.
Biocon is addressing global medical needs through a portfolio of differentiated and high quality, life-saving biotherapeutics.
1 day ago · Biocon Biologics Ltd. is considering raising 40 billion rupees to 45 billion rupees ($540 million) from India’s local-currency bond market in a few months, according to people familiar with the ...
Biocon Biologics Ltd on Monday announced that it has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies ...
